BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 11501527)

  • 21. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
    Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
    DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
    Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
    Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
    Llinas P; Le Du MH; Gårdsvoll H; Danø K; Ploug M; Gilquin B; Stura EA; Ménez A
    EMBO J; 2005 May; 24(9):1655-63. PubMed ID: 15861141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes.
    Huai Q; Zhou A; Lin L; Mazar AP; Parry GC; Callahan J; Shaw DE; Furie B; Furie BC; Huang M
    Nat Struct Mol Biol; 2008 Apr; 15(4):422-3. PubMed ID: 18376415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
    Ploug M; Rahbek-Nielsen H; Ellis V; Roepstorff P; Danø K
    Biochemistry; 1995 Oct; 34(39):12524-34. PubMed ID: 7548000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
    Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
    Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycosylation profile of a recombinant urokinase-type plasminogen activator receptor expressed in Chinese hamster ovary cells.
    Ploug M; Rahbek-Nielsen H; Nielsen PF; Roepstorff P; Dano K
    J Biol Chem; 1998 May; 273(22):13933-43. PubMed ID: 9593742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crystal structure of the urokinase receptor in a ligand-free form.
    Xu X; Gårdsvoll H; Yuan C; Lin L; Ploug M; Huang M
    J Mol Biol; 2012 Mar; 416(5):629-41. PubMed ID: 22285761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.
    Hillig T; Engelholm LH; Ingvarsen S; Madsen DH; Gårdsvoll H; Larsen JK; Ploug M; Danø K; Kjøller L; Behrendt N
    J Biol Chem; 2008 May; 283(22):15217-23. PubMed ID: 18362146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
    Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
    J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.
    Bürgle M; Koppitz M; Riemer C; Kessler H; König B; Weidle UH; Kellermann J; Lottspeich F; Graeff H; Schmitt M; Goretzki L; Reuning U; Wilhelm O; Magdolen V
    Biol Chem; 1997; 378(3-4):231-7. PubMed ID: 9165076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.
    Ploug M
    Curr Pharm Des; 2003; 9(19):1499-528. PubMed ID: 12871065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling.
    Tarui T; Andronicos N; Czekay RP; Mazar AP; Bdeir K; Parry GC; Kuo A; Loskutoff DJ; Cines DB; Takada Y
    J Biol Chem; 2003 Aug; 278(32):29863-72. PubMed ID: 12754207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Yeast expression and phagemid display of the human urokinase plasminogen activator epidermal growth factor-like domain.
    Stratton-Thomas JR; Min HY; Kaufman SE; Chiu CY; Mullenbach GT; Rosenberg S
    Protein Eng; 1995 May; 8(5):463-70. PubMed ID: 8532668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
    Olson D; Pöllänen J; Høyer-Hansen G; Rønne E; Sakaguchi K; Wun TC; Appella E; Danø K; Blasi F
    J Biol Chem; 1992 May; 267(13):9129-33. PubMed ID: 1315748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
    Ploug M; Gårdsvoll H; Jørgensen TJ; Lønborg Hansen L; Danø K
    Biochem Soc Trans; 2002 Apr; 30(2):177-83. PubMed ID: 12023847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.
    Sato S; Kopitz C; Schmalix WA; Muehlenweg B; Kessler H; Schmitt M; Krüger A; Magdolen V
    FEBS Lett; 2002 Sep; 528(1-3):212-6. PubMed ID: 12297307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms.
    Stepanova V; Mukhina S; Köhler E; Resink TJ; Erne P; Tkachuk VA
    Mol Cell Biochem; 1999 May; 195(1-2):199-206. PubMed ID: 10395084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.
    Chang AW; Kuo A; Barnathan ES; Okada SS
    Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1855-60. PubMed ID: 9848876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.
    Høyer-Hansen G; Rønne E; Solberg H; Behrendt N; Ploug M; Lund LR; Ellis V; Danø K
    J Biol Chem; 1992 Sep; 267(25):18224-9. PubMed ID: 1381366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.